Biomelbourne Network company information, Employees & Contact Information

Myrio Therapeutics joins Penn Medicine and NYU Langone in collaboration to advance solid tumor T cell immunotherapies BioMelbourne Network

MTPConnect signs cooperation agreement with Saudi Ministry of Health to boost collaboration BioMelbourne Network

Swinburne and partners pioneer AI-driven model to advance precision medicine in muscular dystrophy BioMelbourne Network

RMIT University develops cancer-targeting nanodots in international breakthrough BioMelbourne Network

Telix agent Zircaix® featured in global guidelines for renal imaging BioMelbourne Network

Snoretox wins the 2025 Innovation Award at the Animal Health Summit in Kansas city BioMelbourne Network

Chimeric Therapeutics partners with Viral Vector Manufacturing Facility to boost GMP viral vector production BioMelbourne Network

Immuron launches PROIBS® in Australia BioMelbourne Network

Immutep Receives FDA Fast Track Designation for Efti for First Line Non-Small Cell Lung Cancer BioMelbourne Network

Nutromics unveils world-first real-time multiplexed antibiotic monitoring breakthrough BioMelbourne Network

BioForum – New horizons: Navigating the future of Victoria’s life sciences industry BioMelbourne Network

Chimeric Therapeutics reports tumour reduction in CHM CDH17 Phase 1/2 trial BioMelbourne Network

RMIT’s 3D-printed diamond titanium device to power next generation implants BioMelbourne Network

Chimeric Therapeutics’ CHM CDH17 Granted FDA Fast Track Designation BioMelbourne Network

Led by Monash University, national Connect-TBI initiative to transform care for traumatic brain injury BioMelbourne Network

Our Strategic Plan 2025 – 2028 BioMelbourne Network

Telix Pharmaceuticals launches new Prostate Cancer Imaging Agent in U.S. BioMelbourne Network

Cureator allocates $15.7 million to advance dementia and cognitive decline innovations BioMelbourne Network

Starpharma secures $855 million cancer therapy partnership with Genentech BioMelbourne Network

Planet Innovation forms strategic alliance with Meiban to deliver integrated CDMO Services BioMelbourne Network

Nucleus Network acquires Hammersmith Medicines Research BioMelbourne Network

Cartherics awarded at 2025 Asia Pacific Cell & Gene Therapy Excellence Awards BioMelbourne Network

Noxopharm receives green light for HERACLES clinical trial BioMelbourne Network

2026 Women in Leadership Awards Launch – Leading through uncertainty BioMelbourne Network

CSL’s Andembry™ wins FDA Approval as first-of-its-kind monthly preventative for Hereditary Angioedema BioMelbourne Network

4D Medical secures FDA clearance for CT VQ lung imaging technology BioMelbourne Network

Amplia Therapeutics announces additional partial response in Pancreatic Cancer trial BioMelbourne Network

WEHI researchers announce breakthrough in Long COVID treatment BioMelbourne Network

Cartherics secure patent from China for enhancing immune cell function BioMelbourne Network

BioForum – Advancing challenging biologics: BsAb, TsAb and RDC/ADC Innovations BioMelbourne Network

Cartherics unveils state-of-the-art cleanroom facility for cell therapy manufacturing BioMelbourne Network

Atmo Biosciences gas capsule receives FDA clearance BioMelbourne Network

BioSymposium: Innovations in technologies – Implantables, Neurotech and Diagnostics BioMelbourne Network

Inoviq’s new Cancer treatments kills 88% of Breast and Lung Cancer Cells in lab tests BioMelbourne Network

CBE Pure Solutions receives TGA licence to manufacture sterile clinical trial liquids for Phase 2 and 3 clinical trials BioMelbourne Network

2025 BioSymposium sponsors: Innovations in Technologies – Implantables, Neurotech, and Diagnostics BioMelbourne Network

La Trobe University opens biosensor research hub following $4.7 million grant BioMelbourne Network

4D Medical Secured Major Contract with Intermountain Health for AI-Based Pulmonary Hypertension Analysis BioMelbourne Network

University of Melbourne App advances early Cerebral Palsy diagnosis through at-home screening BioMelbourne Network

Brandon Capital secures over $430M in final close of sixth life sciences investment fund BioMelbourne Network

BioForum – The smart health revolution: Rewiring care pathways BioMelbourne Network

Akaal Pharma Pty Ltd Announces Positive Phase-2 Results for Treatment of Atopic Dermatitis and Associated Pruritus BioMelbourne Network

Nutromics secures $7.5 million to advance lab-on-a-patch® platform BioMelbourne Network

NRFC Invests $27 Million in PolyActiva to Combat Glaucoma BioMelbourne Network

La Trobe University unveils AI Supercomputer for medical innovation BioMelbourne Network

BioMelbourne Network announces new Board Chair appointment BioMelbourne Network

Nominations open for the prestigious BioMelbourne Network 2026 Women in Leadership Awards BioMelbourne Network

Careers Hub launches to showcase diverse medical research career pathways BioMelbourne Network

University of Melbourne receives $4.4 million funding boost from AEA program BioMelbourne Network

Monash Biotech awarded $750,000 from Brandon BioCatalyst’s CUREator incubator BioMelbourne Network

AMMA Virtual Forum: Building the foundation for Better Health Made Here BioMelbourne Network

Connection, courage and change: Inside the 2025 BioMelbourne Network Connecting Women Lunch BioMelbourne Network

Florey Institute awarded $494,000 to advance groundbreaking “FeBI” quantum iron test BioMelbourne Network

Monash University partners with South Korea’s K-Bio Lab Hub to establish first Australian biotech launchpad BioMelbourne Network

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy BioMelbourne Network

Chimeric Therapeutics Receives $2.5 Million Advance on FY25 R&D Tax Incentive BioMelbourne Network

Ego Pharmaceuticals expands local manufacturing with $156 Million investment BioMelbourne Network

NRFC allocates $150 million to partner with Brandon Capital and advance Australian medical innovation BioMelbourne Network

INOVIQ announces early ovarian cancer screening breakthrough BioMelbourne Network

University of Melbourne awarded $9 million for three new NHMRC Centres of Research Excellence BioMelbourne Network

Radium Capital unleashes $400m war chest for Aussie innovators BioMelbourne Network

WEHI identifies potential HTLV-1 treatment in collaborative study with Doherty Institute BioMelbourne Network

Oncology One, Pfizer, WEHI, Cancer Therapeutics CRC and partners advance Australian-discovered KAT6 inhibitor into Phase 3 breast cancer trial BioMelbourne Network

BioNTech clinical trial platform launched at Peter Mac to expand cancer patient access across Victoria BioMelbourne Network

MoU signed between St Vincent’s Hospital Melbourne and Sichuan Provincial People’s Hospital Enhances Research Collaboration with China BioMelbourne Network

Brandon BioCatalyst backed by $33 million grant to support biotech startups BioMelbourne Network

Chubb celebrates 20-year anniversary and launches new premier insurance package BioMelbourne Network

Biointelect awarded $33 Million to lead national research commercialisation initiative BioMelbourne Network

Adherium has commenced production and market release of the new, next generation Ellipta sensor BioMelbourne Network

Breakthrough IBD treatment heads into clinical trials BioMelbourne Network

Inosi Therapeutics announces $968,192 in TTRA funding with support from IP Group and BioCurate BioMelbourne Network

ANDHealth secures $33 million to expand leading digital health commercialisation program BioMelbourne Network

RMIT University unveils wearable device that heals “remotely” BioMelbourne Network

Starpharma receives positive feedback from FDA on DEP® SN38 clinical pathway for platinum-resistant ovarian cancer BioMelbourne Network

BioMelbourne Network Women in Leadership Awards celebrate diversity, innovation and global impact made in Australia BioMelbourne Network

Wavewise Analytics awarded $996,995 in funding through TTRA initiative BioMelbourne Network

Monash University to lead $25 million mobile CT scanner development project BioMelbourne Network

Monash University’s $7 Million Grant to Improve Atrial Fibrillation Treatment in Australia BioMelbourne Network

Brandon Capital opens second funding round for its Cureator Incubator program BioMelbourne Network

CSL Behring’s Victorian facility wins global pharmaceutical manufacturing award BioMelbourne Network

U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B BioMelbourne Network

Opthea Completes COAST Final Week 52 Patient Visit BioMelbourne Network

Peter MacCallum Cancer Centre Announces Promising Prostate Cancer Therapy Results BioMelbourne Network

Australia’s TGA Approves Registration of CSL’s ANDEMBRY for the Prevention of Recurrent Hereditary Angioedema Attacks BioMelbourne Network

2024 BioMelbourne Network annual general meeting and networking event – SOLD OUT BioMelbourne Network

Melbourne-based EBS secures FDA Approval for World-First Leadless Wise CRT System BioMelbourne Network

Kynetyka’s DVTect technology secures Canadian patent BioMelbourne Network

BioForum – BioNTech: From concept to clinical trials BioMelbourne Network

Shaping The Future Of Our Medical Research Workforce BioMelbourne Network

Investing In Medtech So Patients Can Breathe Easier BioMelbourne Network

Florey Researchers Secure $4.9 Million Grant for Promising New Heart Surgery Treatment BioMelbourne Network

Australian Medtech Manufacturing Alliance strengthens with new steering group members announced BioMelbourne Network

The Undergraduate Research Opportunities Program BioMelbourne Network

Symposium – New approaches in oncology drug development: Innovation, translation & commercialisation BioMelbourne Network

CSL Announces New Research Acceleration Initiative Awardees BioMelbourne Network

2025 BioMelbourne Network Annual General Meeting and Networking Event BioMelbourne Network

Ovarian Cancer Test Delivers Outstanding Diagnostic Performance BioMelbourne Network

Applications Open: CSIRO ON Prime BioMelbourne Network

Amplia enters into preclinical collaboration with Korean specialist drug screening company Next&Bio BioMelbourne Network

$10 million boost from Australian Cancer Research Foundation for state-of-the-art scanning technology BioMelbourne Network